Cognition Therapeutics completes Type C FDA meeting for zervimesine in DLB; discusses Phase 2b endpoints

COGNITION THERAPEUTICS INC

Type C meeting with FDA held on Jan 21, 2026 for zervimesine (CT1812) in dementia with Lewy bodies.
Discussed clinically meaningful endpoints for proposed Phase 2b study in mild-to-moderate DLB.
FDA meeting minutes expected later this quarter; no specific outcome disclosed.
Zervimesine is an oral once-daily investigational drug targeting Aβ and α-synuclein toxicity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.